Mackenzie Financial Corp Has $1,195,000 Stake in Vertex Pharmaceuticals Incorporated (VRTX)

Mackenzie Financial Corp decreased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 88.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,697 shares of the pharmaceutical company’s stock after selling 108,410 shares during the period. Mackenzie Financial Corp’s holdings in Vertex Pharmaceuticals were worth $1,195,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Capital World Investors boosted its position in Vertex Pharmaceuticals by 2.8% in the third quarter. Capital World Investors now owns 22,292,383 shares of the pharmaceutical company’s stock worth $1,944,119,000 after buying an additional 599,586 shares during the period. BlackRock Institutional Trust Company N.A. boosted its position in Vertex Pharmaceuticals by 2.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 6,492,221 shares of the pharmaceutical company’s stock worth $566,187,000 after buying an additional 144,397 shares during the period. BlackRock Fund Advisors boosted its position in Vertex Pharmaceuticals by 3.9% in the third quarter. BlackRock Fund Advisors now owns 6,262,876 shares of the pharmaceutical company’s stock worth $546,185,000 after buying an additional 234,950 shares during the period. Jennison Associates LLC boosted its position in Vertex Pharmaceuticals by 74.2% in the third quarter. Jennison Associates LLC now owns 5,180,761 shares of the pharmaceutical company’s stock worth $451,814,000 after buying an additional 2,205,961 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Vertex Pharmaceuticals by 0.4% in the third quarter. Bank of New York Mellon Corp now owns 3,035,714 shares of the pharmaceutical company’s stock worth $264,746,000 after buying an additional 13,278 shares during the period. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down 1.25% on Friday, hitting $88.15. 1,633,837 shares of the stock traded hands. The stock has a 50 day moving average of $82.21 and a 200 day moving average of $86.88. The firm’s market capitalization is $21.89 billion. Vertex Pharmaceuticals Incorporated has a 52 week low of $71.46 and a 52 week high of $103.73.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, January 25th. The pharmaceutical company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.06. The business earned $458.71 million during the quarter, compared to analysts’ expectations of $453.40 million. Vertex Pharmaceuticals had a negative net margin of 6.76% and a negative return on equity of 2.15%. During the same period last year, the company posted $0.17 earnings per share. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.67 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was reported by sleekmoney and is owned by of sleekmoney. If you are viewing this story on another domain, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this story can be accessed at http://sleekmoney.com/mackenzie-financial-corp-has-1195000-stake-in-vertex-pharmaceuticals-incorporated-vrtx/1656252.html.

VRTX has been the subject of a number of research reports. Janney Montgomery Scott initiated coverage on shares of Vertex Pharmaceuticals in a report on Thursday, November 17th. They issued a “neutral” rating and a $98.00 price target for the company. Vetr raised shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and set a $87.67 price target for the company in a report on Monday, November 21st. Robert W. Baird reissued a “positive” rating on shares of Vertex Pharmaceuticals in a report on Friday. Barclays PLC lowered shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $100.00 to $90.00 in a report on Tuesday, November 29th. Finally, Maxim Group reissued a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, February 3rd. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $100.94.

In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 8,000 shares of the firm’s stock in a transaction on Wednesday, January 11th. The shares were sold at an average price of $82.48, for a total value of $659,840.00. Following the completion of the sale, the director now directly owns 276,225 shares in the company, valued at $22,783,038. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Joshua S. Boger sold 6,500 shares of the firm’s stock in a transaction on Wednesday, November 23rd. The stock was sold at an average price of $86.47, for a total transaction of $562,055.00. Following the completion of the sale, the director now owns 274,725 shares of the company’s stock, valued at $23,755,470.75. The disclosure for this sale can be found here. Insiders sold 53,500 shares of company stock valued at $4,330,000 over the last 90 days. Corporate insiders own 1.90% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/mackenzie-financial-corp-has-1195000-stake-in-vertex-pharmaceuticals-incorporated-vrtx/1656252.html

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *